Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes

Patrick Serruys; Yoshinobu Onuma; John Ormiston; Bernard de Bruyne; Evelyn Regar; Dariusz Dudek; Leif Thuesen; Pieter Smits; Bernard Chevalier; Dougal McClean; Jacques Koolen; Stephan Windecker; Robert Whitbourn; Ian Meredith; Cecile Dorange; Susan Veldhof; Karine Miquel-Hebert; Richard Rapoza; Hector Garcia-Garcia

doi:10.1161/CIRCULATIONAHA.110.970772

Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes

Patrick Serruys, Yoshinobu Onuma, John Ormiston, Bernard de Bruyne, Evelyn Regar, Dariusz Dudek, Leif Thuesen, Pieter Smits, Bernard Chevalier, Dougal McClean, Jacques Koolen, Stephan Windecker, Robert Whitbourn, Ian Meredith, Cecile Dorange, Susan Veldhof, Karine Miquel-Hebert, Richard Rapoza, Hector Garcia-Garcia

Medicine Monash Health

Research output: Contribution to journal › Article › Research › peer-review

300 Citations (Scopus)

Abstract

BACKGROUND: The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with bare metal stents. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified.

Original language	English
Pages (from-to)	2301 - 2312
Number of pages	12
Journal	Circulation
Volume	122
Issue number	22
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.110.970772
Publication status	Published - 2010

Access to Document

10.1161/CIRCULATIONAHA.110.970772

Cite this

Serruys, P., Onuma, Y., Ormiston, J., de Bruyne, B., Regar, E., Dudek, D., Thuesen, L., Smits, P., Chevalier, B., McClean, D., Koolen, J., Windecker, S., Whitbourn, R., Meredith, I., Dorange, C., Veldhof, S., Miquel-Hebert, K., Rapoza, R., & Garcia-Garcia, H. (2010). Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation, 122(22), 2301 - 2312. https://doi.org/10.1161/CIRCULATIONAHA.110.970772

Serruys, Patrick ; Onuma, Yoshinobu ; Ormiston, John ; de Bruyne, Bernard ; Regar, Evelyn ; Dudek, Dariusz ; Thuesen, Leif ; Smits, Pieter ; Chevalier, Bernard ; McClean, Dougal ; Koolen, Jacques ; Windecker, Stephan ; Whitbourn, Robert ; Meredith, Ian ; Dorange, Cecile ; Veldhof, Susan ; Miquel-Hebert, Karine ; Rapoza, Richard ; Garcia-Garcia, Hector. / Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. In: Circulation. 2010 ; Vol. 122, No. 22. pp. 2301 - 2312.

@article{57b6f640aaf34bc8b64f40844824f3ca,

title = "Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes",

abstract = "BACKGROUND: The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with bare metal stents. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified.",

author = "Patrick Serruys and Yoshinobu Onuma and John Ormiston and {de Bruyne}, Bernard and Evelyn Regar and Dariusz Dudek and Leif Thuesen and Pieter Smits and Bernard Chevalier and Dougal McClean and Jacques Koolen and Stephan Windecker and Robert Whitbourn and Ian Meredith and Cecile Dorange and Susan Veldhof and Karine Miquel-Hebert and Richard Rapoza and Hector Garcia-Garcia",

year = "2010",

doi = "10.1161/CIRCULATIONAHA.110.970772",

language = "English",

volume = "122",

pages = "2301 -- 2312",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams & Wilkins",

number = "22",

}

Serruys, P, Onuma, Y, Ormiston, J, de Bruyne, B, Regar, E, Dudek, D, Thuesen, L, Smits, P, Chevalier, B, McClean, D, Koolen, J, Windecker, S, Whitbourn, R, Meredith, I, Dorange, C, Veldhof, S, Miquel-Hebert, K, Rapoza, R & Garcia-Garcia, H 2010, 'Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes', Circulation, vol. 122, no. 22, pp. 2301 - 2312. https://doi.org/10.1161/CIRCULATIONAHA.110.970772

Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. / Serruys, Patrick; Onuma, Yoshinobu; Ormiston, John; de Bruyne, Bernard; Regar, Evelyn; Dudek, Dariusz; Thuesen, Leif; Smits, Pieter; Chevalier, Bernard; McClean, Dougal; Koolen, Jacques; Windecker, Stephan; Whitbourn, Robert; Meredith, Ian; Dorange, Cecile; Veldhof, Susan; Miquel-Hebert, Karine; Rapoza, Richard; Garcia-Garcia, Hector.

In: Circulation, Vol. 122, No. 22, 2010, p. 2301 - 2312.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes

AU - Serruys, Patrick

AU - Onuma, Yoshinobu

AU - Ormiston, John

AU - de Bruyne, Bernard

AU - Regar, Evelyn

AU - Dudek, Dariusz

AU - Thuesen, Leif

AU - Smits, Pieter

AU - Chevalier, Bernard

AU - McClean, Dougal

AU - Koolen, Jacques

AU - Windecker, Stephan

AU - Whitbourn, Robert

AU - Meredith, Ian

AU - Dorange, Cecile

AU - Veldhof, Susan

AU - Miquel-Hebert, Karine

AU - Rapoza, Richard

AU - Garcia-Garcia, Hector

PY - 2010

Y1 - 2010

N2 - BACKGROUND: The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with bare metal stents. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified.

AB - BACKGROUND: The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with bare metal stents. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified.

U2 - 10.1161/CIRCULATIONAHA.110.970772

DO - 10.1161/CIRCULATIONAHA.110.970772

M3 - Article

VL - 122

SP - 2301

EP - 2312

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 22

ER -